This content is machine translated Steatotic liver disease GLP-1RA in MASH – what’s new? Metabolic dysfunction-associated steatohepatitis (MASH) corresponds tothe liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no...…
View Post 4 min This content is machine translated Obesity Extent of weight reduction is prognostically relevant According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases. Obesity-related multimorbidity is...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 5 min This content is machine translated Metabolic Dysfunction-Associated Steatotic Liver Disease Cardiology and hepatology in one boat Metabolic dysfunction has far-reaching negative effects on the body, which can manifest as cardiovascular and liver disease. Traditionally, these conditions have been treated in an organ-centered manner, resulting in isolated…
View Post 6 min This content is machine translated Obesity therapy Why lifestyle modification alone is not effective According to current understanding, obesity is considered a multifactorial chronic disease. The overriding goals of treatment are to improve the general state of health and weight-associated diseases or risk factors.…
View Post 5 min This content is machine translated Obesity The pounds tumble under incretin-based therapies Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the…
View Post 5 min This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
View Post 4 min This content is machine translated Renal effects of empagliflozin Combination with semaglutide does not reduce albuminuria more than Empa mono SGLT2 inhibitors and GLP1 receptor agonists (GLP1-RA) are antidiabetic drugs with the potential to preserve kidney function. Their different mechanisms of action suggest that combination therapy could have additive or…
View Post 3 min This content is machine translated Type 2 diabetes: PIONEER REAL Switzerland study Semaglutide in oral form convinces in everyday practice In the non-interventional PIONEER REAL Switzerland study, adult type 2 diabetics treated with oral semaglutide as part of routine clinical care achieved clinically significant improvement in glycemic control with no…
View Post 10 min This content is machine translated GLP-1 agonists continue to gain ground Semaglutide in patients with obesity and heart failure It has long been known that the active ingredient class of glucagon-like peptide-1 agonists (GLP-1) reduces cardiovascular consequences in diabetics and leads to significant weight loss in patients with obesity.…
